The AA genotype of the regulatory BCL2 promoter polymorphism (-938C>A) is associated with a favorable outcome in lymph node - Negative invasive breast cancer patients

Clinical Cancer Research

Volumn 13, Issue 19, 2007, Pages 5790-5797

  Bachmann, Hagen S ^a,b   Otterbach, Friedrich ^a,b   Callies, Rainer ^a,b   Nückel, Holger ^a,b   Bau, Maja ^a   Schmid, Kurt W ^a,b   Siffert, Winfried ^a,b   Kimmig, Rainer ^a,b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; FEMALE; GENOTYPE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK; TIME FACTORS; TREATMENT OUTCOME;

EID: 35348870611     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2673     Document Type: Article

References (30)

1. Kumar R, Vadlamudi RK, Adam L. Apoptosis in mammary gland and cancer. Endocr Relat Cancer 2000;7:257-69.
2. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997;3:614-20.
3. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-56.
4. Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ 2006;13:1351-9.
5. Faderl S, Keating MJ, Do KA, et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002;16:1045-52.
6. Ofner D, Riehemann K, Maier H, et al. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer 1995;72:981-5.
7. Buglioni S, D'Agnano I, Cosimelli M, et al. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. Int J Cancer 1999;84:545-52.
8. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994;69:135-9.
9. Zhang GJ, Kimijima I, Tsuchiya A, Abe R. The role of bcl-2 expression in breast carcinomas (review). Oncol Rep 1998;5:1211-6.
10. Young RL, Korsmeyer SJ. A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol Cell Biol 1993;13:3686-97.
11. Seto M, Jaeger U, Hockett RD, et al. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 1988;7:123-31.
12. Park BL, Kim LH, Cheong HS, et al. Identification of variants in cyclin D1 (CCND1) and B-cell CLL/lymphoma 2 (BCL2). J Hum Genet 2004;49:449-54.
13. Nückel H, Frey UH, Bau M, et al. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 2007;109:290-7.
14. Ellis I, Schnitt S, Sastre-Garau X, Bussolati G, Tavassoli F, Eusebi V. Invasive breast carcinoma. In: World Health Organization classification of tumours. Tumours of the breast and female genital organs. Tavassoli FA, Devilee P, editors. Lyon; IARC Press: 2003. p.13-59.
15. Sobin LH, Wittekind C. International Union against Cancer. TNM classification of malignant tumours. 6th edition. New York: Wiley-Liss; 2002.
16. Bachmann HS, Siffert W, Frey UH. Successful amplification of extremely GC-rich promoter regions using a novel "slowdown PCR" technique. Pharmacogenetics 2003;13:759-66.
17. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004;9:606-16.
18. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. Epub 2007 Mar 22.
19. Seemayer CA, Breuer E, Kroll G, Markus-Sellhaus S, Reineke TH, Mittermayer C. Incidence and tumour stages of breast cancer in the region of Aachen, Germany. Eur J Cancer Care (Engl) 2002;11:16-24.
20. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast CancerTrialists' Collaborative Group. Lancet 1992;339:71-85.
21. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast CancerTrialists' Collaborative Group. Lancet 1992;339:1-15.
22. Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABPB-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996;14:1982-92.
23. Ludwig Breast Cancer Study Group. Toxic effects of early adjuvant chemotherapy for breast cancer. Lancet 1983;2:542-4.
24. Yang Q, Sakurai T, Yoshimura G, et al. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncol Rep 2003;10:121-5.
25. Callagy GM, Pharoah PD, Pinder SE, et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006;12:2468-75.
26. Thomadaki H, Talieri M, Scorilas A. Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Lett 2007;247:48-55.
27. Silvestrini R, Veneroni S, Daidone MG, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
28. Berardo MD, Elledge RM, de MC, Clark GM, Osborne CK, Allred DC. Bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 1998;82:1296-302.
29. Papadopoulos K. Targeting the Bcl-2 family in cancer therapy. Semin Oncol 2006;33:449-56.
30. Nahta R, Esteva FJ. Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer. Semin Oncol 2003;30:143-9.